ER expression and its role in breast cancer progression is well established, and therapeutics to ER have a major role in the treatment of breast cancer patients. We have identified a role of CAFs in the regulation of ER expression, and through paracrine effects upregulate ER in TNBC cells. The identification of ER expression non-invasively is also possible with 18F-FES PET, and this has been used in a range of clinical trials to guide therapy. The mechanisms of transcriptional regulation of ER expression and results of trials of 18F-FES PET will be presented.
Prof Andrew Scott's clinical and research interests are in molecular imaging of cancer, target discovery and therapeutics development, and conduct of first-in-human and multi-centre clinical trials. He is a Fellow of the Royal Australasian College of Physicians, Fellow of the Australian Academy of Health and Medical Sciences, Fellow of the Australian Institute of Company Directors, and in 2017 was awarded Member (AM) in the General Division of the Order of Australia. Prof Andrew Scott has published 453 peer reviewed papers and 28 book chapters, is an inventor on 27 patents, and has received over $40 million in peer reviewed grant funding in the last 5 years.
